RESEARCH TRIANGLE PARK, N.C., July 22, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2024 financial results on Monday, August 5, 2024. BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update. The live call may be accessed by dialing 1-844-481-2942 for domestic callers and 1-412-317-1866 for international callers. A live webcast ...

Olivier Le Moal/iStock via Getty Images BioCryst Pharmaceuticals (NASDAQ:BCRX) is a biotechnology company developing complement-mediated and rare disease treatments. The company leverages a structure-guided drug design process that integrates biology and medicinal chemistry to generate therapeutics for diseases with unmet medical needs. BCRX has Orladeyo (berotralstat), which represents 95.8% of total revenues, and royalties from Rapivab (Peramivir) injections. Unfortunately, BCRX is heavily leveraged, ...

BioCryst Pharmaceuticals (BCRX) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following ...

RESEARCH TRIANGLE PARK, N.C., July 09, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the General Directorate of Medicines, Supplies and Drugs (DIGEMID) in Peru has granted approval for oral, once-daily ORLADEYO® (berotralstat) for the prophylaxis of hereditary angioedema (HAE) attacks in adults and pediatric patients 12 years of age or older. "We continue to work alongside our partner, Pint Pharma, to bring ORLADEYO to people living with HAE who are in need of n ...

Core Insights - BioCryst Pharmaceuticals announced new data on ORLADEYO® (berotralstat) for hereditary angioedema (HAE) treatment to be presented at the EAACI meeting in Valencia, Spain from May 31 to June 3, 2024 [1] Group 1: Product Information - ORLADEYO® (berotralstat) is the first and only oral therapy specifically designed to prevent HAE attacks in patients aged 12 years and older [2] - The drug works by decreasing the activity of plasma kallikrein, with a recommended dosage of one capsule per day [2] Group 2: Clinical Data Presentation - Two abstracts will be presented at the EAACI meeting: 1. Adverse Health Outcomes and Patient and Physician Perspectives of Attenuated Androgen Use in HAE [1] 2. Effectiveness and Safety of Berotralstat in Patients with HAE with Normal C1 Inhibitor: A European Case Series [1] Group 3: Safety Information - ORLADEYO is indicated for prophylaxis to prevent HAE attacks but not for the treatment of acute attacks [3][4] - Common adverse reactions include abdominal pain, vomiting, diarrhea, back pain, and gastroesophageal reflux disease [5] - A reduced dosage of 110 mg is recommended for patients with moderate or severe hepatic impairment [5]

RESEARCH TRIANGLE PARK, N.C., May 13, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Federal Commission for Protection against Health Risks (COFEPRIS) in Mexico has granted approval for oral, once-daily ORLADEYO® (berotralstat) for the prophylaxis of hereditary angioedema (HAE) attacks in adults and pediatric patients 12 years of age or older. "With this decision by COFEPRIS, ORLADEYO is now approved in four countries in the pan-Latin America region. We are p ...

RESEARCH TRIANGLE PARK, N.C., May 09, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new real-world evidence on the use of oral, once-daily ORLADEYO® (berotralstat) demonstrating that patients with hereditary angioedema (HAE) in the United States experience significant reductions in healthcare resource utilization (HRU) after beginning treatment with ORLADEYO. The study was presented in a poster at the 2024 International Society for Pharmacoeconomics and Outcomes Rese ...

Table of Contents Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock BCRX Nasdaq Global Select Market UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________________ to ...

A better-than-expected first quarter and a goal of profitability and positive cash flow by the end of 2025 brought on a bit of a rally.For the most part, U.S. stocks had a good Monday, with the bellwether S&P 500 index confidently marching more than 1% higher. But BioCryst Pharmaceuticals (BCRX 18.43%) and its investors had a really good day, as the company delivered a first quarter that convincingly beat analyst estimates.The market rewarded this performance by pushing BioCryst's share price more than 18% ...

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q1 2024 Earnings Call Transcript May 6, 2024 8:30 AM ET Company Participants John Bluth - IR Jon Stonehouse - CEO Charlie Gayer - CCO Helen Thackray - Chief R&D Officer Anthony Doyle - CFO Conference Call Participants Maury Raycroft - Jefferies Tazeen Ahmad - Bank of America Serge Belanger - Needham & Company Liisa Bayko - Evercore ISI Stacy Ku - TD Cowen Gena Wang - Barclays Francois Brisebois - Oppenheimer Jon Wolleben - JMP Securities Chris Raymond - Piper San ...